189747-34-0 Usage
Uses
Used in Pharmaceutical Industry:
Pyrimido[5,4-d]pyrimidine, 2,8-dichlorois used as a pharmaceutical intermediate for the development of new drugs. Its unique structure and potential biological activities make it a promising candidate for the treatment of various diseases.
Used in Organic Synthesis:
Pyrimido[5,4-d]pyrimidine, 2,8-dichlorois used as a key building block in organic synthesis. Its reactive chlorine atoms and fused-ring system allow for the formation of various derivatives with diverse chemical properties, which can be further utilized in the synthesis of complex organic molecules.
Used in Medicinal Chemistry Research:
Pyrimido[5,4-d]pyrimidine, 2,8-dichlorois used as a research compound in medicinal chemistry. Its unique structure and potential biological activities make it an interesting target for studying the structure-activity relationships of various drug candidates and for the development of novel therapeutic agents.
Used in Drug Design and Optimization:
Pyrimido[5,4-d]pyrimidine, 2,8-dichlorois used in drug design and optimization processes. Its specific chemical and pharmacological properties can be exploited to improve the potency, selectivity, and pharmacokinetic properties of drug candidates, leading to the development of more effective and safer medications.
Check Digit Verification of cas no
The CAS Registry Mumber 189747-34-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,9,7,4 and 7 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 189747-34:
(8*1)+(7*8)+(6*9)+(5*7)+(4*4)+(3*7)+(2*3)+(1*4)=200
200 % 10 = 0
So 189747-34-0 is a valid CAS Registry Number.
InChI:InChI=1/C6H2Cl2N4/c7-5-4-3(10-2-11-5)1-9-6(8)12-4/h1-2H
189747-34-0Relevant academic research and scientific papers
NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE
-
, (2021/06/26)
The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.
Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor
Rewcastle, Gordon W.,Bridges, Alexander J.,Fry, David W.,Rubin, J. Ronald,Denny, William A.
, p. 1820 - 1826 (2007/10/03)
A series of 6-substituted 4-anilinopyrimido[5,4-d]pyrimidines has been prepared and shown to be potent inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). These compounds are structurally related to the pyrido[3,2-d]
